Clinical Trial Detail

NCT ID NCT03520686
Title QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Altor BioScience
Indications

lung non-small cell carcinoma

Therapies

ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium

ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

ALT-803 + Pembrolizumab

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST